Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and derivatives thereof. The compounds are useful as antivirals.

Abstract: The present invention relates to certain amino acid esters of the purine nucleoside acyclovir, pharmaceutically acceptable salts thereof and their use in the treatment and prophylaxis of herpes virus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.

Abstract: A group of 2-aminopurine compounds, which have in the 6-position a hydrogen and in the 9-position an acyclic moiety ##STR1## wherein X is oxygen or sulphur and Y is hydrogen or CH.sub.2 OH (provided than when X is oxygen Y may not be hydrogen), are converted enzymatically in vivo into the corresponding 6-hydroxy (i.e. guanine) derivatives which are potent antiviral compounds. The enzymatic conversion may also be effected ex vivo (i.e. in vitro) as a method of synthesizing the corresponding 6-hydroxy derivatives.

Abstract: The present invention relates to certain 2',3'-dideoxynucleosides and pharmaceutically acceptable derivatives thereof, methods for preparing them, their use in the treatment and prophylaxis of viral, especially retroviral, infections, and pharmaceutical formulations containing them.

Abstract: This invention discloses a group of compounds of formula (I) ##STR1## wherein R.sup.1 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, COOR.sup.4 (R.sup.4 is H or C.sub.1-4 alkyl) or trifluoromethyl; R.sup.2, R.sup.5 and R.sup.6 are the same or different and can be hydrogen, hydroxy, OCOR.sup.7 (wherein R.sup.7 is hydrogen, C.sub.1-4 alkyl, phenyl optionally substituted) or halo; and R.sup.3 is hydrogen, COR.sup.4, C.sub.3-6 cycloalkyl or C.sub.1-4 alkyl or alkenyl; R.sup.2 may also be a phosphate group and pharmaceutically acceptable salts thereof which have been found to have analgesic activity. In addition, these compounds have antiinflammatory, antipyretic, antihypertensive and vasodilatory activity in varying degrees. Some of these compounds also have antiprotozoal and antiviral properties.

Abstract: The novel 2-aminopurine derivatives disclosed herein which have a hydrogen atom in the 6-position and an acyclic chain ##STR1## in the 9-position [wherein X=O or S, Y=H or CH.sub.2 OR and R=H or ##STR2## wherein R.degree.=H, C.sub.1-16 alkyl (preferably C.sub.1-6 alkyl), optionally substituted aralkyl or optionally substituted aryl, provided at least one R is ##STR3## are converted in vivo by the action of xanthine oxidase/dehydrogenase or aldehyde oxidase and esterase enzymes into the corresponding 6-hydroxy compounds wherein R=H, which are potent antiviral compounds.

Abstract: The novel compound 6-deoxyacyclovir is enzymatically converted to acyclovir by xanthine oxidase/dehydrogenase or aldehyde oxidase in vivo, i.e. within the body of the animal being treated. The enzymatic conversion may also be effected ex vivo (i.e. in vitro) as a method of synthesizing acyclovir.

Abstract: The novel 2-aminopurine derivatives disclosed herein which have a hydrogen atom in the 6-position and an acyclic chain ##STR1## in the 9-position [wherein X=O or S, Y=H or CH.sub.2 OR and R=H or ##STR2## wherein R.degree.=H, C.sub.1-16 alkyl (preferably C.sub.1-6 alkyl), optionally substituted aralkyl or optionally substituted aryl, provided at least one R is ##STR3## are converted in vivo by the action of xanthine oxidase/dehydrogenase or aldehyde oxidase and esterase enzymes into the corresponding 6-hydroxy compounds wherein R=H, which are potent antiviral compounds.

Abstract: The novel compound 6-deoxyacyclovir is enzymatically converted to acyclovir by xanthine oxidase/dehydrogenase or aldehyde oxidase in vivo, i.e. within the body of the animal being treated. The enzymatic conversion may also be effected ex vivo (i.e. in vitro) as a method of synthesizing acyclovir.

Abstract: The novel compounds 3-deaza-2'-deoxyadenosine and certain of its derivatives and their pharmaceutically acceptable salts have anti-inflammatory activity as well as immune response suppression activity. 3-Deaza-2'-deoxyadenosine and certain of its intermediates are synthesized by the enzyme catalyzed reaction of the appropriately substituted 3-deazapurine with a 2'-deoxyribose donor.

Abstract: The novel compounds 3-deaza-2'-deoxyadenosine and certain of its derivatives and their pharmaceutically acceptable salts have anti-inflammatory activity as well as immune response suppression activity. 3-Deaza-2'-deoxyadenosine and certain of its intermediates are synthesized by the enzyme catalyzed reaction of the appropriately substituted 3-deazapurine with a 2'-deoxyribose donor.

Abstract: 4-Substituted-3-deazapurine ribosides are prepared by the enzymatically catalyzed reaction of 4-substituted-3-deazapurine with a ribose donor.

Abstract: 4-Substituted alkyl-1-.alpha.-D-ribofuransylpyrazole-(3,4-d) pyrimidines are active against coccidia in vivo and unlike the 4-methylthio analogue, are non-toxic. Methods for preparing and using the compounds, intermediates in the preparation and compositions of the compounds are also described.

Abstract: 4-Alkenylthio-1-.beta.-D-ribofuranosylpyrazolo[3,4-d]-pyrimidines are active against coccidia in vivo, and unlike the 4-methylthio analogue, are non-toxic. Methods for the preparation and use of the compounds, intermediates in the preparation and formulations of the compounds are also described.

Abstract: Thymidine phosphorylase counteracts antagonists to antifolate agents in media used for testing the susceptibility of bacteria to anti-folate antimicrobial agents. A solution of thymidine phosphorylase may be stabilized by addition of inorganic phosphate and uracil, the stabilization being most effective at pH7. Furthermore, bovine serum albumin is added to prevent loss of enzymic activity on filtration. The solution may be kept sterile by addition of sodium or potassium azide.

Abstract: A bacterial culture medium used in testing for the susceptibility of bacteria to anti-folate, anti-bacterial agents is substantially improved for this use by the incorporation therein of purified thymidine phosphorylase of bacterial origin.